Targeting c-Met, Remegen ADC drug RC108 was approved for clinical use in the United States for the treatment of solid tumors

On December 29, Remegen Biopharmaceutical (Yantai) Co., Ltd. announced that RC108 for injection of the innovative antibody conjugate drug (ADC) independently developed by the company has obtained clinical trial approval from the US Food and Drug Administration (FDA) to carry out clinical research in patients with solid tumors with positive c-Met expression.

RC108 is an ADC independently developed by Remegen for the treatment of patients with c-Met positive solid tumors. The product is composed of C-Met-targeting antibody, linker and small molecule cytotoxin, which can mediate the endocytosis of antibody by targeting and binding to C-Met-positive tumor cells, so as to effectively deliver cytotoxins to cancer cells and achieve better tumor killing effect. In November 2020, Remegen was approved by the NMPA to conduct a Phase I clinical trial of RC108 for c-Met-positive advanced solid tumors in China. At present, the test is progressing smoothly, and the overall safety is controllable.

C-Met is a receptor tyrosine kinase that, when bound to its ligand (hepatocyte growth factor), activates a variety of different cell signaling pathways involved in tumor proliferation, movement, migration, and invasion. Studies have shown that the expression of c-Met gene is often associated with the poor prognosis of a variety of solid tumors, and many tumor patients have C-Met overexpression and gene amplification during the occurrence and metastasis of their tumors.